PI3K inhibition, resulted in PD-L1 downregulation in different cancer types including renal cell carcinoma through HGF/c-Met [36], KRAS- or EGFR-mutated NSCLC [42] and melanoma [32]. Here, KRAS is linked to non-small cell lung carcinoma.